stockrow
Saturday 7 November 2026
Export OTLK’s income statement to Excel — free account
Outlook Therapeutics, Inc.
OTLK Healthcare Biotechnology
Outlook Therapeutics, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $1.4 million.
- Revenue
- −99.4%
- EPS
- +72.7%
- Free cash flow
- −76.5%
- Total debt
- −47.1%
Quarter to June 2026, against a year earlier
0.43
0.01
−2.27%
Follow OTLK
Alert me
Outlook Therapeutics, Inc. (OTLK) P/E ratio
Outlook Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1.5× (May 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.5×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NBP NovaBridge Biosciences compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| OTLK Outlook Therapeutics, Inc. | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)